.jpeg)
Global deal on TB patent rights agreed, but concerns remain
Click here for article in the Guardian
A global deal on patent rights for tuberculosis (TB) drugs has been agreed, but some alliances have expressed concerns that it will not go far enough to ensure affordable access to these life-saving medicines.
The deal, which was reached at the World Health Organization (WHO) in Geneva, Switzerland, will allow generic drug manufacturers to produce TB drugs without the permission of the patent holders. This is expected to lead to a significant reduction in the price of these drugs, making them more affordable for people in low- and middle-income countries.
However, some alliances, such as the Stop TB Partnership, have expressed concerns that the deal does not go far enough. They argue that it does not include all of the TB drugs that are needed, and that it does not provide enough safeguards to ensure that generic manufacturers will actually produce these drugs.
Another concern is that the deal does not address the issue of data exclusivity. This is a period of time during which the patent holder has exclusive rights to the data generated from clinical trials of a new drug. This can make it difficult for generic manufacturers to develop and register their own versions of these drugs.
Despite these concerns, the deal is a significant step forward in the fight against TB. It is estimated that TB kills 1.5 million people each year, and it is the leading cause of death from a single infectious agent. The agreement could help to make TB treatment more affordable and accessible, and it could save millions of lives.
Here are some of the specific concerns that have been raised:The deal does not include all of the TB drugs that are needed. For example, it does not include bedaquiline, a drug that is considered to be a last resort for people with multidrug-resistant TB.
The deal does not provide enough safeguards to ensure that generic manufacturers will actually produce these drugs. There is a risk that generic manufacturers will not be able to make a profit from producing these drugs, which could lead to them not being available on the market.
The deal does not address the issue of data exclusivity. This could make it difficult for generic manufacturers to develop and register their own versions of TB drugs.
These concerns need to be addressed if the deal is to be successful in making TB treatment more affordable and accessible. The WHO and other stakeholders need to work to ensure that generic manufacturers are able to produce these drugs, and that they are available at a price that people in low- and middle-income countries can afford.
thumb_upthumb_down
tuneshareGoogle it
A global deal on patent rights for tuberculosis (TB) drugs has been agreed, but some alliances have expressed concerns that it will not go far enough to ensure affordable access to these life-saving medicines.
The deal, which was reached at the World Health Organization (WHO) in Geneva, Switzerland, will allow generic drug manufacturers to produce TB drugs without the permission of the patent holders. This is expected to lead to a significant reduction in the price of these drugs, making them more affordable for people in low- and middle-income countries.
However, some alliances, such as the Stop TB Partnership, have expressed concerns that the deal does not go far enough. They argue that it does not include all of the TB drugs that are needed, and that it does not provide enough safeguards to ensure that generic manufacturers will actually produce these drugs.
Another concern is that the deal does not address the issue of data exclusivity. This is a period of time during which the patent holder has exclusive rights to the data generated from clinical trials of a new drug. This can make it difficult for generic manufacturers to develop and register their own versions of these drugs.
Despite these concerns, the deal is a significant step forward in the fight against TB. It is estimated that TB kills 1.5 million people each year, and it is the leading cause of death from a single infectious agent. The agreement could help to make TB treatment more affordable and accessible, and it could save millions of lives.
Here are some of the specific concerns that have been raised:The deal does not include all of the TB drugs that are needed. For example, it does not include bedaquiline, a drug that is considered to be a last resort for people with multidrug-resistant TB.
The deal does not provide enough safeguards to ensure that generic manufacturers will actually produce these drugs. There is a risk that generic manufacturers will not be able to make a profit from producing these drugs, which could lead to them not being available on the market.
The deal does not address the issue of data exclusivity. This could make it difficult for generic manufacturers to develop and register their own versions of TB drugs.
These concerns need to be addressed if the deal is to be successful in making TB treatment more affordable and accessible. The WHO and other stakeholders need to work to ensure that generic manufacturers are able to produce these drugs, and that they are available at a price that people in low- and middle-income countries can afford.
thumb_upthumb_down
tuneshareGoogle it
Comments
Post a Comment
If you are a member of XUNICEF, you can comment directly on a post. Or, send your comments to us at xunicef.news.views@gmail.com and we will publish them for you.